Orserdu (elacestrant) was backed for the treatment of postmenopausal women and men with locally advanced or metastatic breast cancer with ESR1 mutation, an indication approved by the FDA in ...
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback